Inventiva Taps Biopharma Veteran Benecchi as COO Ahead of Key MASH Trial Readout
Event summary
- Inventiva appoints Chris Benecchi as Chief Operating Officer, effective August 31, 2026.
- Benecchi brings 30 years of biopharmaceutical leadership, including roles at Sage Therapeutics and Alexion.
- Appointment comes ahead of pivotal NATiV3 Phase 3 topline study results for lanifibranor in MASH, expected Q4 2026.
- Potential U.S. launch of lanifibranor anticipated in 2028, subject to regulatory approval.
- Inventiva is strategically building organization and commercial capabilities for potential commercialization.
The big picture
Inventiva's appointment of Chris Benecchi as COO underscores its strategic pivot from clinical development to commercial readiness. The move comes as the biopharmaceutical company prepares for the pivotal Phase 3 readout of its lead candidate, lanifibranor, in the rapidly evolving MASH market. Benecchi's extensive experience in launching innovative therapies positions Inventiva to navigate the complex regulatory and commercial landscape ahead.
What we're watching
- Trial Timing
- Whether the NATiV3 Phase 3 topline results will meet expectations in Q4 2026 and their impact on regulatory approval prospects.
- Commercialization Pace
- The speed at which Inventiva can scale its operational and commercial capabilities ahead of a potential 2028 U.S. launch.
- Market Dynamics
- How Inventiva positions lanifibranor in the competitive and access-challenged MASH market.